

RESEARCH ARTICLE

Potential involvement of neutrophils in human thyroid cancer

Maria Rosaria Galdiero^{1,2,3*}, Gilda Varricchi^{1,2,3}, Stefania Loffredo^{1,2,3}, Claudio Bellevicine⁴, Tiziana Lansione^{1,2,3}, Anne Lise Ferrara^{1,2,3}, Raffaella Iannone^{1,2,3}, Sarah di Somma^{1,2,3}, Francesco Borriello^{1,2,3,5}, Eduardo Clery⁴, Maria Triassi⁴, Giancarlo Troncione⁴, Gianni Marone^{1,2,3,6*}

1 Department of Translational Medical Sciences (DiSMET), University of Naples Federico II, Naples, Italy, **2** Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy, **3** WAO Center of Excellence, University of Naples Federico II, Naples, Italy, **4** Department of Public Health, University of Naples Federico II, Naples, Italy, **5** Department of Medicine, Division of Infectious Diseases, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, **6** Institute of Experimental Endocrinology and Oncology "Gaetano Salvatore" (IEOS), National Research Council (CNR), Naples, Italy

* mariarosaria.galdiero@unina.it (MRG); marone@unina.it (GM)



OPEN ACCESS

Citation: Galdiero MR, Varricchi G, Loffredo S, Bellevicine C, Lansione T, Ferrara AL, et al. (2018) Potential involvement of neutrophils in human thyroid cancer. PLoS ONE 13(6): e0199740. <https://doi.org/10.1371/journal.pone.0199740>

Editor: Fabrizio Mattei, Istituto Superiore di Sanità, ITALY

Received: February 19, 2018

Accepted: June 13, 2018

Published: June 28, 2018

Copyright: © 2018 Galdiero et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported by grants from the Regione Campania CISI-Lab Project, CR&ME Project and TIMING Project (to G.M.).

Competing interests: The authors have declared that no competing interests exist.

Abstract

Background

Neutrophil functions have long been regarded as limited to acute inflammation and the defense against microbes. The role(s) of neutrophils in cancer remain poorly understood. Neutrophils infiltrate tumors and are key effector cells in the orchestration of inflammatory responses. Thyroid cancer (TC) is the most recurrent endocrine malignant tumor and is responsible for 70% of deaths due to endocrine cancers. No studies are so far available on the role of neutrophils in TC.

Objective

Our purpose was to study the involvement of tumor-associated neutrophils in TC.

Methods

Highly purified human neutrophils (>99%) from healthy donors were stimulated *in vitro* with conditioned media derived from TC cell lines TPC1 and 8505c (TC-CMs). Neutrophil functions (e.g., chemotaxis, activation, plasticity, survival, gene expression, and protein release) were evaluated.

Results

TC-derived soluble factors promoted neutrophil chemotaxis and survival. Neutrophil chemotaxis toward a TC-CM was mediated, at least in part, by CXCL8/IL-8, and survival was mediated by granulocyte-macrophage colony-stimulating factor (GM-CSF). In addition, each TC-CM induced morphological changes and activation of neutrophils (e.g., CD11b and CD66b upregulation and CD62L shedding) and modified neutrophils' kinetic properties. Furthermore, each TC-CM induced production of reactive oxygen species, expression of

proinflammatory and angiogenic mediators (CXCL8/IL-8, VEGF-A, and TNF- α), and a release of matrix metalloproteinase 9 (MMP-9). Moreover, in TC patients, tumor-associated neutrophils correlated with larger tumor size.

Conclusions

TC cell lines produce soluble factors able to “educate” neutrophils toward an activated functional state. These data will advance the understanding of the molecular and cellular mechanisms of innate immunity in TC.

Introduction

Thyroid cancer (TC) is a frequent solid tumor type worldwide and the most recurrent cancer of the endocrine system [1]. Indeed, TC is responsible for 90% of the endocrine malignant tumors and 70% of deaths due to endocrine tumors. In the past 5 years, the incidence of TC has progressively increased [2]. The prognosis of TC patients is highly variable, with small TCs showing only small possibility of tumor-specific morbidity or mortality, and with anaplastic TC being one of the most fatal solid tumors [3].

The relation between chronic inflammation and TC has long been described. Indeed, a combination of immune mediators and cellular effectors has been uncovered in TC and is related to tumor progression and clinical outcomes [4]. During activation of the MAPK and NF- κ B pathways by oncogenic drivers, such as the RET/PTC rearrangement, RAS, and BRAF, thyrocytes are induced to produce a number of cytokines and chemokines that sustain tumor growth and progression [5,6,7]. Moreover, under resting conditions and/or as a consequence of proinflammatory stimuli, transformed thyrocytes produce and release inflammatory factors such as CXC chemokines (e.g., CXCL1, CXCL8, CXCL9, and CXCL10), which promote the recruitment and activation of tumor-infiltrating leukocytes [8,9,10,11].

Among tumor-infiltrating myeloid cells, macrophages are the best-characterized cells involved in tumor initiation and progression [12,13]. Tumor-associated macrophages (TAMs) manifest functional characteristics similar to those of alternative (M2) macrophages. In TC, TAMs show increased density and positively correlate with lymph node metastasis, larger tumor size, dedifferentiation, capsular invasion, extrathyroid extension, and reduced survival among the patients [14,15,16,17,18].

Neutrophils (polymorphonuclear leukocytes; PMNs) are well known leading actors in an acute inflammatory response and in the defense against extracellular microbes [19]. Nonetheless, a growing number of lines of evidence is shedding new light on the multiple roles of PMNs in the immune and inflammatory responses [12,20,21].

Indeed, studies have described the presence of tumor-associated neutrophils (TANs) in cancer, which correlate with patients' clinical outcomes [22,23,24,25,26,27,28]. Nevertheless, their functional roles at the various steps of tumor initiation and progression are still a matter of debate. For instance, TANs have been associated with genetic instability and neutrophil-derived cytokines (e.g., OSM, VEGF) or granule proteins (e.g., neutrophil elastase) play many roles in the promotion of cancer cell proliferation, invasive behavior, and the angiogenic switch [29,30,31,32,33]. In contrast, antitumor neutrophils were recently proposed that can kill tumor cells, to stimulate the T- cell-dependent anti-tumoral immunity, and inhibit angiogenesis have been recently proposed [28,34,35,36]. Therefore, to date, the participation of

neutrophils in different types of cancer is still controversial and its deciphering remains an important challenge.

The prognosis of patients with TC remains difficult because of heterogeneity of this pathology manifesting distinct clinical and molecular characteristics [37]. The ratio of the peripheral-blood neutrophil count to the lymphocyte count (neutrophil-to-lymphocyte ratio; NLR) has been associated with tumor development and progression [38]. In patients with TC, a higher NLR correlates with larger tumor volume and higher risk of recurrence but is not effective at discriminating benign from malignant lesions [39]. Moreover, the NLR does not correlate with the risk of occult metastasis or with patients' survival [40]. Thus, the prognostic significance of NLR in TC remains uncertain. To our knowledge, there is no information concerning the occurrence, functions, and prognostic significance of TANs in TC.

In this study, for the first time, we investigated the presence of infiltrating neutrophils in human TC and analyzed the phenotypic and functional characteristics of "tumor-educated" neutrophils. In particular, we took advantage of an *in vitro* model to elucidate the functional interactions between TC cells and human neutrophils. We found that TC cells recruited neutrophils and significantly improved their survival. Moreover, TC cells upregulated neutrophils' proinflammatory activities as well as the expression of factors that can retain the ability to promote tumor progression. Finally, we found that PMNs infiltrated human TC and correlated with tumor size, further supporting the potential tumor-promoting role of TANs in TC.

Materials and methods

Cell cultures and preparation of tumor-conditioned media

Human thyroid tumor cell lines TPC1 (papillary thyroid cancer), 8505c (anaplastic thyroid cancer) and Nthy-ori 3-1 (immortalized thyroid follicular epithelial cell line derived from normal adult thyroid tissue that has been transfected with a plasmid encoding the SV40 large T gene) were from ATCC, cultured and maintained in DMEM supplemented with 10% of heat-inactivated fetal calf serum (FCS; endotoxin level <0.1 EU/ml), 50 U/ml penicillin/streptomycin, and 2 mM L-glutamine (Euroclone, Milan, Italy) at 37°C in a humidified atmosphere containing 5% of CO₂ and 95% of air. Conditioned media were prepared and used as follows. Cells were seeded at 10–20% confluence in tissue culture plates. Once the cells reached confluence of 85–90%, the cell culture medium was replaced with a serum-free fresh medium. After 24 hours, this conditioned medium was harvested, filtered (0.20 µm pore size filter), and stored at –20°C. All the cell lines were routinely checked for mycoplasma contamination.

Neutrophil purification and culture

The study protocol involving the use of human blood cells was approved by the Ethical Committee of the University of Naples Federico II, and written informed consent was obtained from blood donors according to the principles expressed in the Declaration of Helsinki. Granulocytes were isolated from buffy coats of healthy donors (HBsAg[–], HCV[–], and HIV[–]) obtained from a leukapheresis unit. Leukocytes were separated from erythrocytes by dextran sedimentation. Neutrophils were purified by Ficoll-Paque Histopaque[®]-1077 (Sigma Aldrich, Milan, Italy) density gradient centrifugation (400 × *g* for 30 minutes at 22°C), followed by Percoll (Sigma Aldrich, Milan, Italy) (65%) density gradient centrifugation (660 × *g* for 20 minutes at 22°C), as previously described [41]. Finally, neutrophils were isolated from granulocytes (to reach >99% purity) by positive elimination of all contaminating cells using the EasySep Neutrophil Enrichment Kit (StemCell Technologies, Vancouver, Canada) [42].

These cells were >99% neutrophils as evaluated by flow-cytometric analysis with the following antibodies: anti-CD3, anti-CD14, anti-CD15, anti-CD11b, anti-CD193 (Miltenyi Biotec,

Germany), anti-CD62L (L-Selectin) (BD Biosciences, USA), and anti-CD66b (Biolegend, CA, USA). Samples were analyzed on the MACSQuant Analyzer 10 (Miltenyi Biotec, Germany) and in the FlowJo software, v.10. Doublets and debris were excluded from the analysis. Data were expressed as a percentage of positive cells or median fluorescence intensity [43]. Spontaneous activation of neutrophils was evaluated by analyzing CD11b and L-selectin expression by flow-cytometric analysis before and after neutrophil purification; only L-selectin⁺CD11b^{low} (nonactivated) neutrophils were chosen for the study (data not shown).

Quantification of soluble factors in culture supernatants or total protein lysates

CXCL8/IL-8, granulocyte-macrophage colony-stimulating factor (GM-CSF), and MMP-9 concentrations in cell-free conditioned media or total protein lysates (0.1% Triton X-100) were assessed in duplicate with commercially available ELISA kits (R&D Systems). MMP-9 levels in total protein lysates were normalized to total protein concentrations as determined by a Bradford protein assay (Bio-Rad) and expressed in nanograms of protein per milligram of total protein. A microplate reader (Tecan, Austria, GmbH) was used to determine sample absorbance at 450 nm. The ELISA sensitivity is 31.1–2,000 pg/ml for CXCL8/IL-8, 15.6–1,000 pg/ml for GM-CSF, and 31.3–2,000 pg/ml for MMP-9.

Cell migration assay

Migration of neutrophils toward TC-conditioned media (TC-CMs) was evaluated by means of a 3 μ m cell culture inserts in 96-well companion plates (Corning Costar). The companion plates were loaded with 235 μ l of a conditioned medium or control medium (serum-free DMEM). PMNs (2.5×10^6 neutrophils/ml per 75 μ l) were placed in the inserts and allowed to migrate at 37°C and 5% CO₂ for 1 hour. At the end of the incubation, the cells were centrifuged and resuspended in 100 μ l of PBS and counted by flow cytometry (MACSQuant Analyzer 10, Miltenyi Biotec, Germany). In some experiments, neutrophils were preincubated with mouse monoclonal anti-CXCR1 and/or anti-CXCR2 blocking antibodies at 10 μ g/ml (clone 42705 and clone 48311 respectively, R&D Systems) or the corresponding control isotype (R&D Systems) at 37°C and 5% CO₂ for 60 minutes and then subjected to the migration assay as already described above.

Apoptosis assay and morphological analysis of neutrophils

Purified neutrophils (2×10^6 cells/ml) were cultured in a TPC1 or 8505c conditioned medium with or without the mouse monoclonal anti-GM-CSF blocking antibody at 10 μ g/ml (clone 3209, R&D Systems) or the corresponding control isotype (R&D Systems). For each time point, neutrophils were stained with fluorescein isothiocyanate (FITC)-conjugated annexin V and propidium iodide (PI) according to the protocol provided by the manufacturer (Miltenyi Biotec, Germany). Quantification was performed on a MACS Quant flow cytometer (Miltenyi Biotec, Germany). Live cells were assumed to be double-negative annexin V⁻PI⁻ cells. Analysis was performed by means of FlowJo v.10.

Flow cytometry

These experiments were conducted with purified neutrophils. For activation experiments, the cells were kept in RPMI 1640 with 10% of FCS for 1 h and stimulated with one of TC-CMs for 90 minutes. Then, the cells were stained (20 minutes, 4°C) in PBS plus 1% FCS (Euroclone, Milan, Italy) (staining buffer containing antibodies). The following antibodies were employed:

VioBlue-conjugated anti-human CD15 (clone VIMC6, dilution 1:10, from Miltenyi Biotec, Germany), phycoerythrin (PE)-conjugated anti-human CCR3 (clone 5E8, dilution 1:10, from Biolegend, CA, USA), allophycocyanin (APC)-conjugated anti-human CD66b (clone G10F5, dilution 1:20, from Biolegend, CA, USA), APC-conjugated anti-human CD11b (clone ICRF44, dilution 1:50, from eBiosciences), and FITC-conjugated anti-human CD62L (clone DREG-56, dilution 1:10, from BD Biosciences, USA). The samples were studied on the MACS Quant Analyzer 10 (Miltenyi Biotec) and in FlowJo v.10. Doublets and debris (identified based on forward and side scatter properties) were excluded from the analysis. Data are expressed as a percentage of positive cells or median fluorescence intensity [43].

Reactive oxygen species (ROS) production

Neutrophils (2×10^6 cells/ml) were resuspended in the RPMI 1640 medium with 2% of fetal bovine serum (FBS) and antibiotics at 37°C and 5% CO₂. The cells were incubated for 30 minutes after the addition of 10 µg/ml H₂DCF-DA (Life Technologies, Milan, Italy). H₂DCF-DA is a fluorogenic dye that allows researchers to determine hydroxyl peroxy and other ROS activities within the cell. Once diffused into the cell, H₂DCF-DA is deacetylated by cellular esterases to a nonfluorescent molecule, which is oxidized by ROS into 2',7'-dichlorofluorescein (DCF). DCF is highly fluorescent and can be detected by fluorescence spectroscopy with maximum excitation and emission wavelengths of 492–495 and 517–527 nm, respectively. The cells were washed in PBS and resuspended in a TC-CM, control medium, or phorbol myristate acetate (PMA; 10 ng/ml) and immediately seeded in a 96-well plate and placed in a EnSpire Multi-mode Plate Reader (Perkin Elmer). DCF mean fluorescence intensity was measured at an excitation wavelength of 492–495 nm and emission at 517–527 nm. The ability of a TC-CM to induce cytoplasmic ROS-catalyzed oxidation of DCFH in neutrophils was measured as compared to the positive control (PMA; Sigma-Aldrich, Milan, Italy) and to the negative control (the medium alone).

RNA isolation and real-time RT-PCR

Total RNA was extracted with the TRIzol Reagent (Thermo Fisher Scientific) and quantified on a Nanodrop ND-1000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA). Reverse transcription was performed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City CA, USA). Real-time RT-PCR was performed by means of Universal SYBR Green Supermix (Bio-Rad) on a CFX96 Real-time detection system (Bio-Rad). Relative gene expression was calculated by the ΔC_t (relative expression) method. Each C_t value was normalized to the respective *GAPDH* C_t value. Target-specific primers for *GAPDH*, *CXCL8/IL-8*, *TNF- α* , and *VEGF-A* were synthesized and purified by Custom Primers (Life Technologies, Milan, Italy).

Fluorescence, time-lapse, and high-content microscopy

Microscopy experiments were conducted with the Operetta High-Content Imaging System (PerkinElmer), similarly to previously described procedures [43]. Neutrophils were cultured in 96-well black CellCarrier plates (PerkinElmer). For time-lapse experiments, neutrophils were cultured overnight. Within this time window, digital phase contrast images of 15 fields/well were captured every 15 minutes via a 20 \times objective. To quantify cell morphological features, bright-field snapshots were taken at 15 fields/well. PhenoLOGIC (PerkinElmer) was employed for image segmentation and for calculating the single-cell morphological results by the dedicated STAR analysis sequence [43]. STAR morphology is an enhanced series of algorithms that provide a statistically powerful set of properties for analyzing phenotypes by characterizing cell

morphology and the distribution of intensity within regions. The STAR method offers the possibility to calculate symmetry properties, threshold compactness, axial properties, radial properties, and a profile [43,44].

Immunohistochemistry

We retrieved 32 thyroid tumors from the archives of the Department of Public Health, Pathology Division, University of Naples Federico II. These cases included papillary thyroid carcinomas ($n = 23$), follicular adenomas ($n = 1$), Hürthle cell adenomas ($n = 4$), follicular carcinoma ($n = 3$), and one case of medullary thyroid carcinoma. Four-micron slices of formalin-fixed paraffin-embedded cell blocks were placed on charged slides, then deparaffinized and dehydrated. To detect the infiltrating neutrophils, we employed the anti-CD66b monoclonal antibody (clone G10F5, dilution 1:100) as a primary antibody [22,27,28]. After heat-induced antigen retrieval, the slides were processed by Benchmark XT Autostainer (Ventana, Roche) using the UltraView Polymer Detection kit. Negative controls were implemented by omitting the primary antibody. Whole-tumor section CD66b⁺ neutrophils were counted and scored by a trained pathologist at 200 \times magnification. Only CD66b⁺ neutrophils infiltrating the tumorous lesions were considered, avoiding those within the vascular spaces. The CD66b⁺ neutrophil count in tumor samples was distributed according to the tumor size. The median value of tumor size served as a cutoff. The numbers of CD66b⁺ neutrophils were also studied regarding a possible correlation with the dimensions (in cm) of each thyroid nodule.

Statistical analysis

The data are expressed as mean \pm SEM of the indicated number of experiments. Statistical analysis was performed in Prism 6 (GraphPad Software). Values from groups were compared by Student's *t* test or repeated-measures one-way or two-way analysis of variance corrected for multiple comparisons as appropriate. Pearson's analysis was carried out to test the correlation between CD66b⁺ tumor infiltrating neutrophils and tumor size. Differences were assumed to be statistically significant when the *p* value was < 0.05 .

Results

TC-derived soluble mediators induced neutrophil chemotaxis

In the first group of *in vitro* experiments, we studied the ability of TC cell lines to direct migration of PMNs, referred to as chemotaxis. Highly purified human PMNs from peripheral blood of healthy donors were allowed to migrate toward a TC-CM from papillary TC cell line TPC1 or from the anaplastic TC cell line 8505c or toward a control medium. After 1 hour of incubation, migrating cells were counted by flow cytometry. TC-CM was found to induce greater directed migration of PMNs as compared to the control medium (Fig 1A). These results suggested that soluble factors released by TC induced PMN chemotaxis.

Thyroid cancer cell lines autocrinously produce a large amount of CXCL chemokines [8,10,45], which can be responsible for neutrophil chemotaxis [20,46]. CXCL8/IL-8 was found in large amounts (~ 10 ng/ml) in TC-CM (Fig 1B). CXCL8/IL-8 retains a well-known chemotactic activity for neutrophils, acting through CXCR1/2 and playing a pivotal role in the tumor microenvironment (TME) [47,48]. To investigate the mechanisms of PMN chemotaxis, neutralizing antibodies against CXCL8/IL-8 receptors CXCR1 and/or CXCR2 were used. Thus, PMNs were allowed to migrate toward a TC-CM in the presence of a CXCR1-blocking and/or CXCR2-blocking antibody or the related isotype (control). The results showed that




Fig 1. TC-derived soluble mediators induced neutrophil chemotaxis. A. Neutrophil chemotaxis toward TC-CM or the control medium was evaluated using 3 μ m cell culture inserts in 96-well companion plates. Neutrophils (2.5×10^6 cells/ml per 75 μ l) were allowed to migrate (37°C, 60 minutes) toward a TC-CM or the control medium (235 μ l per well). At the end of the incubation, the cells were centrifuged and resuspended in PBS (100 μ l) and counted by flow cytometry. Data are expressed as migratory cells relative to the control (mean \pm SEM of five independent experiments), **p < 0.01. B. The CXCL8/IL-8 release by TPC1 and 8505c cells was evaluated by an ELISA in a TC-CM or in the control medium. Results are expressed as mean \pm SEM of seven independent experiments; ****p < 0.001. C and D. Chemotactic activity of neutrophils *via* a TPC1-derived (C) or 8505c-derived (D) conditioned medium was analyzed in the presence of blocking antibodies directed against CXCR1 and/or CXCR2 (10 μ g/ml) or the related isotype control. Migratory neutrophils were counted by flow cytometry. The results are expressed as a percentage of isotype control (mean \pm SEM of eight independent experiments); ****p < 0.005; **p < 0.01; *p < 0.05.

<https://doi.org/10.1371/journal.pone.0199740.g001>

blocking of CXCR1 and CXCR2 significantly reduced PMN chemotaxis toward a TC-CM (Fig 1C and 1D).

TC-derived soluble factors promoted neutrophil survival

We next tested whether a TC-CM could modulate PMN lifespan. To investigate the effect of TC cells on PMN survival, highly purified human neutrophils from healthy donors were cultured *in vitro* in a TC-CM or control medium. At different time points (24 and 48 hours) PMNs were stained with FITC-conjugated annexin V and propidium iodide (PI) and subjected to cytofluorimetric analysis. The presence of a TC-CM markedly increased the survival of PMNs as compared to the control medium (Fig 2A and 2B). On day 2, almost all PMNs cultured in the control medium were apoptotic (live cells represented 3.8%). In contrast, a large proportion of PMNs cultured in the presence of a TC-CM were live ($40.9\% \pm 9\%$, $31.7\% \pm 9\%$; mean \pm SEM) cultured in the conditioned medium from cells TPC1 and 8505c, respectively. Fig 2B illustrates representative flow cytometric panels of one out five independent experiments. Interestingly, the presence of the CM derived from the non-tumoral cell line Nthy-ori did not increase the survival of PMNs (S1 Fig). These results suggested that TC cell lines produced soluble mediators that increased PMN survival.

To dissect the molecular mechanism behind this prosurvival effect, we evaluated the presence of soluble factors known to increase the PMN lifespan in a TC-CM. GM-CSF is a well-known determinant of proliferation and differentiation of granulocytes and macrophages [49]. Of note, a large number of cell types, such as endothelial cells, T cells, macrophages, fibroblasts, mesothelial, and epithelial cells as well as tumor cells can produce GM-CSF [50]. To evaluate the molecular mechanism underlying the prosurvival effect of TC-CMs, we evaluated the presence of GM-CSF in TC-CMs by an ELISA. Cells TPC1 and 8505c constitutively produced high levels of GM-CSF, as compared to the control medium (Fig 2C). To assess the relevance of TC-derived GM-CSF in TC-CM for PMN survival, TC-CMs were depleted of GM-CSF with a neutralizing antibody. PMNs were purified and cultured in a TC-CM or the control medium in the presence of an anti-GM-CSF blocking antibody or the relative isotype control. After 24 hours, PMNs were stained with FITC-conjugated annexin V and PI and subjected to cytofluorimetric analysis. Of note, a blocking antibody, anti-GM-CSF, significantly inhibited the prosurvival effect of CM (Fig 2D and 2F). Fig 2E and 2G illustrate representative flow cytometric panels of one out of five independent experiments. Collectively, these data suggested that TC-CMs markedly improved PMN survival because of the presence of GM-CSF.

TC-derived soluble factors induced PMN activation

To determine whether TC-derived soluble factors activate human PMNs, we determined CD11b, CD66b, and CD62L (L-selectin) expression on PMNs by flow cytometry [51,52]. PMNs were stimulated with PMA (as a positive control), with a TC-CM, or with the control medium. PMNs were then stained with antibodies against CD11b, CD66b, and CD62L and evaluated by flow cytometry. Under basal conditions, neutrophils showed minimal expression of CD11b and CD66b, which rapidly increased after incubation with inflammatory agonists, such as PMA (Fig 3A and 3B). TPC1 and 8505c conditioned media also induced CD66b and CD11b upregulation (Fig 3A, 3B, 3G and 3H). On the contrary, under resting conditions, PMNs highly expressed CD62L. In the presence of a TC-CM, the expression of selectin decreased, similarly to the proinflammatory control PMA (Fig 3C and 3I). Collectively, these data indicated that TC-derived soluble factors activated PMNs (CD66b and CD11b upregulation, CD62L shedding). Fig 3D–3I show representative flow cytometry




Fig 2. TC-derived soluble factors promoted neutrophil survival. A. Neutrophils were cultured in a TC-CM or the control medium. At the indicated time points, live cells were evaluated by flow cytometry with FITC-conjugated annexin V and PI. Results were expressed as percentages of live cells (mean ± SEM of five independent experiments); ***p < 0.005; **p < 0.01; *p < 0.05. B. Representative flow cytometric panels of dot plots of PMNs cultured in a TC-CM or control medium and stained with FITC-conjugated annexin V and propidium iodide (PI) at 24 (upper panels) and 48 (lower panels) hours. C. The GM-CSF release by TPC1 and 8505c cells was evaluated by an ELISA in a TC-CM or in the control medium. Results were expressed as mean ± SEM of seven independent experiments; ****p < 0.001; ***p < 0.005. D-F. Neutrophil survival in a TPC1-derived (D-E) or 8505c-derived (F-G) conditioned medium was evaluated in the presence of an anti-GM-CSF blocking antibody or the relative isotype control (10 µg/ml). At 24 hours, live cells were stained with FITC-conjugated annexin V and PI and analyzed by flow cytometry. Figs E and G illustrate representative flow cytometric panels of one out of five independent experiments. The results were expressed as mean ± SEM of five independent experiments; **p < 0.01; *p < 0.05.

<https://doi.org/10.1371/journal.pone.0199740.g002>

panels for Fig 3A (CD11b), 3B (CD66b) and 3C (CD62L), with the specific gating strategy and related histograms (Fig 3G, 3H and 3I, respectively).

TC-derived soluble factors induced MMP-9 release and ROS production

Besides, PMN activation was investigated by evaluation of extracellular and intracellular concentrations of MMP-9 by an ELISA. We measured the extracellular levels of MMP-9 in PMN supernatants of a TC-CM or the control medium. MMP-9 production was not detectable in TC-CMs and in the control medium (Fig 4A). MMP-9 concentration significantly increased




Fig 3. TC-derived soluble factors induced activation of neutrophils. A–C. Neutrophils were stimulated with a TC-CM or the control medium for 90 minutes, stained for neutrophil activation markers CD11b (A), CD66b (B), and CD62L (C) and subjected to cytofluorimetric analysis. The results were expressed as mean fluorescence intensity or percentages of positive cells gated on neutrophils (mean \pm SEM of five independent experiments); *** $p < 0.005$, ** $p < 0.01$, * $p < 0.05$. D–F. Representative flow cytometric panels with respect to the gating strategy of total cells (D), singlets (E) and CD15+ CCR3- neutrophils (F). G–I. Representative histograms illustrating

mean fluorescence intensity (MFI) and cell counts for CD11b (G), CD66b (H) and CD62L (I) for one out of five independent experiments. MFI = mean fluorescence intensity; FMO = fluorescence minus one.

<https://doi.org/10.1371/journal.pone.0199740.g003>

in PMN supernatants after TC-CM stimulation (Fig 4A). In addition, PMNs cultured in a TC-CM showed reduced MMP-9 intracellular content as compared to the negative control and compared to freshly isolated cells (Fig 4B), suggesting that TC-CMs activated PMNs and mediated the MMP-9 release from PMN tertiary granules.




Fig 4. TC-derived soluble factors induced MMP-9 release and ROS production. A and B. Neutrophils were cultured in a TC-CM or the control medium for 18 hours. At the end of the incubation, neutrophils were harvested and centrifuged (600 × g, 4°C, 5 minutes), and the supernatants were collected. The extracellular release of MMP-9 from TC cell lines and neutrophils (A) as well as intracellular concentration of MMP-9 in neutrophils (B) after cell lysis (Triton X-100, 0.1%) were evaluated by an ELISA. The results were expressed as mean ± SEM of five independent experiments; ***p < 0.005; *p < 0.05. C. Neutrophils were incubated with 2',7'-dichlorodihydrofluorescein diacetate (H₂DCFDA, 10 μM, 30 minutes, 37°C), washed, and stimulated with a TC-CM or the control medium. Immediately after the stimulation, the cells were placed in a multimode microplate reader (EnSpire Multimode Plate reader, PerkinElmer), and DCF fluorescence intensity was quantitatively measured for 20 minutes at 2 minutes intervals. The results were expressed as percentages of t₀ (mean ± SEM of five independent experiments); ***p < 0.005; **p < 0.01.

<https://doi.org/10.1371/journal.pone.0199740.g004>




Fig 5. TC-CMs induced morphological changes in neutrophils. Neutrophils were stimulated with a TC-CM or the control medium for 16 hours and then were imaged by means of an Operetta high-content imaging system at 20× magnification. The images were analyzed in the Harmony software with PhenoLOGIC (PerkinElmer) and a dedicated analysis sequence (morphological properties, method STAR) to evaluate cell area (A), roundness (B), radial mean (C), symmetry (D), width-to-length ratio (E), and axial length (F). The results were expressed as an increase or decrease compared to the control (mean ± SEM of five independent experiments); ***p < 0.005.

<https://doi.org/10.1371/journal.pone.0199740.g005>

To test whether neutrophil activation leads to ROS production, we performed a 2',7'-dichlorodihydrofluorescein diacetate (H₂DCF-DA) ROS detection assay. PMNs were labeled with H₂DCF-DA or a control medium. Fig 4C illustrates the kinetics (2 to 20 minutes) of the production of ROS induced by PMA, each TC-CM, and the control medium. ROS production by PMNs was significantly increased by TC-CMs or by PMA. By contrast, the control medium did not induce the production of ROS (Fig 4C). Collectively, these findings suggested that TC-derived soluble factors promoted the release of ROS from human PMNs.

TC-CMs modified morphology and kinetic properties of neutrophils

Morphological cell features are related to cellular functions and have been shown to predict clinical outcomes [53]. Using the high-content imaging approach, we effectively measured and tracked changes of a number of morphological characteristics at the single-cell level and quantitatively determined these morphological feature distributions in response to the culture conditions [43,44]. To this end, PMNs were incubated with a TPC1 or 8505c TC-CM or the control medium for 16 hours at 37°C. For each individual cell, morphological characteristics were assessed. PMNs treated with a TC-CM showed increased their cell area, a greater cell radial mean, and lower width-to-length and axial length ratios and lost their roundness and symmetry (Fig 5A–5F). Thus, morphological changes in PMNs owing to cell attachment and spreading and known to occur after stimulation by inflammatory cytokines and growth factors [53], were observed when the cells were cultured in a TC-CM (Fig 5A–5F).

In addition to evaluating morphological changes at a single time point, we detected fluctuations in cell morphology over time by time-lapse microscopy. To this end, PMNs were




Fig 6. TC-derived soluble factors modified neutrophils' kinetic properties. Neutrophils were stimulated with a TC-CM or the control medium for 18 hours. Within this time window, digital phase contrast images of 15 fields/well were captured every 15 minutes via a 20× objective in the Operetta high-content imaging system. PhenoLOGIC (PerkinElmer) was employed for image segmentation and to calculate the single-cell kinetic properties (A), accumulated distance, (B) speed and straightness (C) in dedicated analysis sequence. The results were expressed as mean ± SEM of six independent experiments; ***p < 0.005; **p < 0.01; *p < 0.05. D-E. Timepoint analyses of time-dependent properties such as current step size (D) and current speed (E) illustrating dynamic changes of the behavior of neutrophils (in presence or absence of TC-CMs) in function of the elapsed time from treatment. The results were expressed as mean ± SEM of six independent experiments; ****p < 0.001.

<https://doi.org/10.1371/journal.pone.0199740.g006>

cultured in a TC-CM or the control medium for 16 hours at a controlled temperature (37°C) and CO₂ levels (5%). Within this time window, digital phase contrast images were captured every 15 minutes. PMNs cultured in a TC-CM showed a reduced overall accumulated distance and an increased speed and straightness (Fig 6A–6C). Moreover, timepoint analyses performed with regard of time-dependent properties such as current step size (Fig 6D) and current speed (Fig 6E), showed that, in the presence of a TC-CM, PMNs displayed increased step size and speed compared to the control medium. Taken together, these results suggest that under the influence of TC-derived soluble mediators, PMNs modified their kinetic properties, taking up less space per time unit and losing their basal random movement.

TC-CMs induced the expression of proinflammatory and angiogenic factors by PMNs

We then evaluated whether the TC-CMs modified neutrophils' gene expression. PMNs stimulated with TC-CM for 18 hours at 37°C manifested increased mRNA levels of genes encoding proinflammatory and proangiogenic molecules such as CXCL8/IL-8, vascular endothelial growth factor A (VEGF-A) and TNF-α (Fig 7A–7C). These data revealed that PMNs




Fig 7. TC-derived soluble factors induced the expression of proinflammatory and angiogenic factors by neutrophils. Human neutrophils were treated with a TC-CM or the control medium for 18 hours. At the end of the incubation, the cells were harvested and lysed for RNA isolation. *CXCL8/IL-8* (A), *VEGF-A* (B), and *TNF-α* (C) mRNA levels were evaluated by real-time PCR. The results are expressed as a fold change relative to the control (mean ± SEM of six independent experiments); **p < 0.01; *p < 0.05.

<https://doi.org/10.1371/journal.pone.0199740.g007>

stimulated with TC-CM upregulated mRNA expression of various proinflammatory and angiogenic factors such as *CXCL8/IL-8*, *VEGF-A*, and *TNF-α*.

Tumor-infiltrating neutrophils positively correlated with tumor size in human TC specimens

Our results showed that a TC-CM recruited PMNs and significantly modified their biological properties. PMNs infiltrate different types of human tumors [23]. With the exception of some case reports [54], to our knowledge, there is no information concerning the presence and significance of tumor-infiltrating PMNs in human TC. Therefore, we assessed the occurrence of CD66b⁺ PMNs by immunohistochemistry in tumorous thyroid tissue samples. To this end, a panel of 32 TC specimens was subjected to immunohistochemical analysis. The age of patients ranged from 23 to 73 years, median 41 years. Lymph node metastasis positivity was found in 46.8% (15/32) of patients during the surgical operation. An anti-CD66b monoclonal antibody, which specifically recognizes human PMNs was used [22,24,28]. Representative examples of cell staining with the anti-CD66b antibody are presented in Fig 8A and 8B. In particular, Fig 8A shows one case of mixed classic-follicular variant papillary thyroid cancer with numerous tumor-infiltrating PMNs, which are organized in clusters within the tumor tissue. Fig 8B shows one case of a classic papillary thyroid carcinoma with a few granulocytes scattered throughout the tumor tissue. An isotype-matched unrelated antibody yielded negative results (not shown). A high CD66b⁺ cell count was significantly associated with a larger tumor volume (p = 0.04, Table 1 and Fig 8C). Thus, PMN density positively correlated with larger tumor size in TC (r = 0.43, p = 0.01; Table 1 and Fig 8D). No correlations between PMN infiltration and other clinical parameters were found (Table 1).

Discussion

In this study, we investigated the possible involvement of PMNs in TC. We found that soluble factors derived from human TC cells can profoundly influence several characteristics of human PMNs. TC-CMs induced PMN chemotaxis through a release of *CXCL8/IL-8*, which acts on its cognate receptors *CXCR1* and *CXCR2* expressed on PMNs. Each TC-CM significantly increased PMN survival via a release of GM-CSF by TC cells. In addition, each TC-CM




Fig 8. The number of tumor-infiltrating neutrophils positively correlated with tumor size in human TC specimens. A and B. Histological analysis of TC specimens stained with a monoclonal anti-CD66b antibody. Whole-tumor section density of CD66b⁺ neutrophils was scored at 200× magnification. Representative cases of papillary thyroid carcinomas with a high (A) and low (B) CD66b⁺ neutrophil count (arrows; hematoxylin counterstaining, 200×). C. CD66b⁺ neutrophil counts in tumor specimens were distributed according to the tumor size. The median value of tumor size served as a cutoff level. Results are shown as the median, the 25th and 75th percentiles (boxes), and 5th and 95th percentiles (whiskers); *p < 0.05, according to the two-tailed Mann-Whitney U test. D. Neutrophil density positively correlated with larger tumor size in TC patients (r = 0.43; p = 0.01; Pearson's correlation test).

<https://doi.org/10.1371/journal.pone.0199740.g008>

induced PMN activation (CD11b and CD66b upregulation and CD62L shedding) and profoundly modified PMN morphology and kinetic properties. Furthermore, each TC-CM induced the production of ROS, expression of proinflammatory and angiogenic factors (CXCL8/IL-8, VEGF-A, and TNF- α), and a release of MMP-9. Moreover, the density of tumor-infiltrating PMNs correlated with TC size.

A number of experimental pieces of evidence have proved that cancer-related inflammation promotes tumor initiation and progression, helping cancers to acquire all the hallmark capabilities, including evasion of immunosurveillance [55,56]. Solid tumors are characterized by an inflammatory profile and the presence of infiltrating immune cells, which together with stromal cells and blood and lymphatic vessels constitute the TME [57,58,59].

Some studies have extensively addressed the function of cells of innate immunity and adaptive immunity in TC [4] and other tumor types [23,59,60,61,62]. In particular, TAMs, dendritic cells, tumor-associated mast cells, myeloid-derived suppressor cells, natural killer (NK)

Table 1. Correlation between the clinical variables and tumor-associated CD66b⁺ neutrophils in thyroid carcinoma.

	CD66b ⁺ Cells (n = 32)		pvalue*
	N	Median Value (IQR)	
Age (years)[§]			
≥ 41	17	16 (3.5–37.5)	0.48
< 41	15	15 (8.75–55.5)	
Sex			
Male	9	10 (5.25–16.75)	0.22
Female	23	22 (8–48)	
Histotype			
Adenomas	5	13 (2.5–66)	0.59
Carcinomas	27	17 (8–41.5)	
Mutational status			
Wild Type	5	40 (13–60)	0.1
Mutated	27	16 (5–35)	
Tumor size (cm)[§]			
≥ 1.3	17	28 (10–54)	0.04
< 1.3	16	9 (5–22)	
T stage			
T1-T2	25	19.5 (8–45)	0.1
T3-T4	7	9 (1.25–14.5)	

IQR = interquartile range;

[§] Median value;

* Mann–Whitney *U* test

<https://doi.org/10.1371/journal.pone.0199740.t001>

cells, invariant natural killer cells, and CD4⁺ and CD8⁺ T cells have been shown to play a role in TC [4,63,64].

PMNs are canonically associated with acute inflammation where they exert a pivotal action against extracellular pathogens [19,65] and for wound repair [66]. Nonetheless, compelling evidence points to a major involvement of PMNs in different types of cancer [22,24,25,28,30,34,35,67], even though their functions are still a matter of debate, and a dual role of neutrophils in tumor biology has been described [59,68,69,70].

Several studies have examined the NLR [39,71,72]; however, these studies have limited relevance because there is increasing evidence of profound differences between peripheral-blood PMNs and TANs [34]. By contrast, to our knowledge, no studies are so far available on the occurrence, significance, and functional roles of neutrophils in human TC. Our results support the observation that human neutrophils can be activated in response to components of the TME in human TC [29,73]. To the best of our knowledge, our study is the first to reveal the presence of neutrophils in human TC, the association between neutrophil infiltration and tumor size in TC patients, and the plasticity of neutrophils under the influence of TC-derived soluble mediators. Indeed, we found that TC cells produce soluble factors able to recruit, prolong the lifespan, and to activate neutrophils. We confirmed that TC cells constitutively produce CXCL8/IL-8 and, accordingly, conditioned media from TC cells exerted chemotactic activity toward neutrophils in a CXCR1/2-dependent manner. In addition, TC cells activated PMNs and prolonged their survival via the production of GM-CSF. Moreover, we demonstrated that TC-CMs induced profound morphological and functional changes of human PMNs.

We found that a TC-CM can prolong the survival, increase activity, and ROS production of human PMNs. These findings suggest that PMNs can acquire a cytotoxic antitumor phenotype under the influence of a TC-CM [34,74]. Quite recently, however, activated neutrophils, with reduced apoptosis and increased ROS production were described in chronic leukemia and non-small cell lung cancer and were found to correlate with poor prognosis among the patients, suggesting that functional activation is not necessarily related to an antitumor phenotype [75,76].

Neutrophils are the main producers of ROS, which are the major antimicrobial tool for these cells. ROS participate in neutrophils' cytotoxic activity against cancer cells [35,74]. Nevertheless, enhanced ROS production by neutrophils limits the NK cell-mediated antibody-dependent cytotoxicity against leukemic cells during anti-CD20 treatment, induces DNA mutations and genotoxicity, and favors drug resistance and systemic T-cell and NK-cell dysfunction [77,78,79]. Collectively, these findings suggest that neutrophil-derived ROS can exert a protumorigenic action. Further studies are needed to test whether different ROS released from activated neutrophils exert a pro- or antitumorigenic activity in TC.

PMNs activated by a TC-CM are a major source of several protumorigenic and angiogenic factors (i.e. VEGF-A, CXCL8/IL-8, and MMP-9) which are known players in cancer-related inflammation [33,80,81,82]. Indeed, neutrophil-derived MMP-9 induces the release of VEGF from the ECM, and neutrophils have been identified as the major source of MMP-9 in different types of human cancer [81,83,84]. Moreover, MMP-9 is released by neutrophils in a TIMP1-free manner, thus providing a powerful proangiogenic factor [85]. Moreover, in a murine model of transplantable melanoma and fibrosarcoma, TANs are the main regulators of angiogenesis and tumor growth because of the expression of VEGF and MMP-9 [29], suggestive of acquisition of a protumor phenotype. Nevertheless, whether a similar neutrophil polarization exists in humans still needs to be assessed.

Of note, we found a correlation between tumor-infiltrating neutrophils and human TC volume. Finally, preliminary experiments indicated that neutrophils promoted the proliferation of TC cell lines (data not shown). Taken together, our findings support the hypothesis that TANs play a protumorigenic role in human TC.

Although our results indicate for the first time possible involvement of neutrophils in human TC, further research is needed to understand their role in tumor initiation and progression. In particular, additional studies are needed to understand which mediators are responsible for TC-driven neutrophil activation as well as to elucidate the mechanisms by which these "tumor-educated neutrophils" can promote TC cell proliferation. Additional studies are needed to understand whether TAN density correlates with clinical parameters (i.e., survival) in different types of TC.

Insights into the molecular and cellular mechanisms underlying PMN infiltration in the TME in various types of TC may lead to the identification of new diagnostic and prognostic markers and perhaps novel therapeutic targets in this frequent endocrine cancer.

Supporting information

S1 Fig. TC-derived soluble factors promoted neutrophil survival. Neutrophils were cultured in a TC-CM, Nthy-ori-CM or the control medium. At the indicated time points, live cells were evaluated by flow cytometry with FITC-conjugated annexin V and PI. Results were expressed as percentages of live cells (mean \pm SEM of four independent experiments); **** $p < 0.001$; * $p < 0.05$; ns = not significant.
(TIFF)

Author Contributions

Conceptualization: Maria Rosaria Galdiero, Gilda Varricchi, Stefania Loffredo, Claudio Bellevicine, Tiziana Lansione, Anne Lise Ferrara, Raffaella Iannone, Sarah di Somma, Francesco Borriello, Eduardo Clery, Maria Triassi, Giancarlo Troncone, Gianni Marone.

Data curation: Maria Rosaria Galdiero, Gilda Varricchi, Stefania Loffredo, Claudio Bellevicine, Tiziana Lansione, Anne Lise Ferrara, Raffaella Iannone, Sarah di Somma, Francesco Borriello, Eduardo Clery, Giancarlo Troncone.

Formal analysis: Maria Rosaria Galdiero, Gilda Varricchi, Stefania Loffredo, Claudio Bellevicine, Raffaella Iannone, Sarah di Somma, Francesco Borriello, Eduardo Clery, Gianni Marone.

Funding acquisition: Maria Triassi, Giancarlo Troncone, Gianni Marone.

Investigation: Maria Rosaria Galdiero, Stefania Loffredo, Claudio Bellevicine, Anne Lise Ferrara, Raffaella Iannone, Sarah di Somma, Francesco Borriello, Eduardo Clery, Maria Triassi.

Methodology: Maria Rosaria Galdiero, Gilda Varricchi, Stefania Loffredo, Claudio Bellevicine, Tiziana Lansione, Anne Lise Ferrara, Raffaella Iannone, Sarah di Somma, Francesco Borriello, Eduardo Clery.

Project administration: Maria Rosaria Galdiero, Claudio Bellevicine, Maria Triassi, Gianni Marone.

Resources: Maria Triassi, Giancarlo Troncone.

Software: Maria Rosaria Galdiero, Gilda Varricchi, Stefania Loffredo, Claudio Bellevicine, Francesco Borriello, Eduardo Clery, Gianni Marone.

Supervision: Maria Rosaria Galdiero, Stefania Loffredo, Francesco Borriello, Maria Triassi, Giancarlo Troncone, Gianni Marone.

Validation: Maria Rosaria Galdiero, Gilda Varricchi, Claudio Bellevicine, Eduardo Clery, Giancarlo Troncone, Gianni Marone.

Visualization: Maria Rosaria Galdiero, Gilda Varricchi, Maria Triassi, Giancarlo Troncone, Gianni Marone.

Writing – original draft: Maria Rosaria Galdiero, Gilda Varricchi, Stefania Loffredo, Claudio Bellevicine, Gianni Marone.

Writing – review & editing: Maria Triassi, Giancarlo Troncone, Gianni Marone.

References

1. Davies L, Welch HG (2014) Current thyroid cancer trends in the United States. *JAMA Otolaryngol Head Neck Surg* 140: 317–322. <https://doi.org/10.1001/jamaoto.2014.1> PMID: 24557566
2. Carling T, Udelsman R (2014) Thyroid cancer. *Annu Rev Med* 65: 125–137. <https://doi.org/10.1146/annurev-med-061512-105739> PMID: 24274180
3. Nabhan F, Ringel MD (2017) Thyroid nodules and cancer management guidelines: comparisons and controversies. *Endocr Relat Cancer* 24: R13–R26. <https://doi.org/10.1530/ERC-16-0432> PMID: 27965276
4. Galdiero MR, Varricchi G, Marone G (2016) The immune network in thyroid cancer. *Oncoimmunology* 5: e1168556. <https://doi.org/10.1080/2162402X.2016.1168556> PMID: 27471646
5. Borriello MG, Alberti L, Fischer A, Degl'innocenti D, Ferrario C, et al. (2005) Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. *Proc Natl Acad Sci U S A* 102: 14825–14830. <https://doi.org/10.1073/pnas.0503039102> PMID: 16203990

6. Bauerle KT, Schweppe RE, Lund G, Kotnis G, Deep G, et al. (2014) Nuclear factor kappaB-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8. *J Clin Endocrinol Metab* 99: E1436–1444. <https://doi.org/10.1210/jc.2013-3636> PMID: 24758177
7. Rotondi M, Coperchini F, Pignatti P, Magri F, Chiovato L (2015) Metformin reverts the secretion of CXCL8 induced by TNF-alpha in primary cultures of human thyroid cells: an additional indirect anti-tumor effect of the drug. *J Clin Endocrinol Metab* 100: E427–432. <https://doi.org/10.1210/jc.2014-3045> PMID: 25590211
8. Rotondi M, Coperchini F, Chiovato L (2013) CXCL8 in thyroid disease: from basic notions to potential applications in clinical practice. *Cytokine Growth Factor Rev* 24: 539–546. <https://doi.org/10.1016/j.cytogfr.2013.08.001> PMID: 24011840
9. Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Piaggi S, et al. (2009) Dysregulation of secretion of CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists. *Endocr Relat Cancer* 16: 1299–1311. <https://doi.org/10.1677/ERC-08-0337> PMID: 19755523
10. Melillo RM, Guarino V, Avilla E, Galdiero MR, Liotti F, et al. (2010) Mast cells have a protumorigenic role in human thyroid cancer. *Oncogene* 29: 6203–6215. <https://doi.org/10.1038/onc.2010.348> PMID: 20729915
11. Passaro C, Borriello F, Vastolo V, Di Somma S, Scamardella E, et al. (2016) The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma. *Oncotarget* 7: 1500–1515. <https://doi.org/10.18632/oncotarget.6430> PMID: 26625205
12. Bonavita E, Galdiero MR, Jaillon S, Mantovani A (2015) Phagocytes as Corrupted Policemen in Cancer-Related Inflammation. *Adv Cancer Res* 128: 141–171. <https://doi.org/10.1016/bs.acr.2015.04.013> PMID: 26216632
13. Mantovani A, Germano G, Marchesi F, Locatelli M, Biswas SK (2011) Cancer-promoting tumor-associated macrophages: new vistas and open questions. *Eur J Immunol* 41: 2522–2525. <https://doi.org/10.1002/eji.201141894> PMID: 21952810
14. Fang W, Ye L, Shen L, Cai J, Huang F, et al. (2014) Tumor-associated macrophages promote the metastatic potential of thyroid papillary cancer by releasing CXCL8. *Carcinogenesis* 35: 1780–1787. <https://doi.org/10.1093/carcin/bgu060> PMID: 24608042
15. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA (2008) Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. *Endocr Relat Cancer* 15: 1069–1074. <https://doi.org/10.1677/ERC-08-0036> PMID: 18719091
16. Kim S, Cho SW, Min HS, Kim KM, Yeom GJ, et al. (2013) The expression of tumor-associated macrophages in papillary thyroid carcinoma. *Endocrinol Metab (Seoul)* 28: 192–198.
17. Jung KY, Cho SW, Kim YA, Kim D, Oh BC, et al. (2015) Cancers with Higher Density of Tumor-Associated Macrophages Were Associated with Poor Survival Rates. *J Pathol Transl Med* 49: 318–324. <https://doi.org/10.4132/jptm.2015.06.01> PMID: 26081823
18. Caillou B, Talbot M, Weyemi U, Pioche-Durieu C, Al Ghuzlan A, et al. (2011) Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma. *PLoS One* 6: e22567. <https://doi.org/10.1371/journal.pone.0022567> PMID: 21811634
19. Jaillon S, Galdiero MR, Del Prete D, Cassatella MA, Garlanda C, et al. (2013) Neutrophils in innate and adaptive immunity. *Semin Immunopathol* 35: 377–394. <https://doi.org/10.1007/s00281-013-0374-8> PMID: 23553214
20. Mantovani A, Cassatella MA, Costantini C, Jaillon S (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. *Nat Rev Immunol* 11: 519–531. <https://doi.org/10.1038/nri3024> PMID: 21785456
21. Galdiero MR, Varricchi G, Loffredo S, Mantovani A, Marone G (2018) Roles of neutrophils in cancer growth and progression. *J Leukoc Biol* 103: 457–464. <https://doi.org/10.1002/JLB.3MR0717-292R> PMID: 29345348
22. Galdiero MR, Bianchi P, Grizzi F, Di Caro G, Basso G, et al. (2016) Occurrence and significance of tumor-associated neutrophils in patients with colorectal cancer. *Int J Cancer* 139: 446–456. <https://doi.org/10.1002/ijc.30076> PMID: 26939802
23. Donskov F (2013) Immunomonitoring and prognostic relevance of neutrophils in clinical trials. *Semin Cancer Biol*.
24. Varricchi G, Granata F, Loffredo S, Genovese A, Marone G (2015) Angiogenesis and lymphangiogenesis in inflammatory skin disorders. *J Am Acad Dermatol* 73: 144–153. <https://doi.org/10.1016/j.jaad.2015.03.041> PMID: 25922287

25. Wikberg ML, Ling A, Li X, Oberg A, Edin S, et al. (2017) Neutrophil infiltration is a favorable prognostic factor in early stages of colon cancer. *Hum Pathol* 68: 193–202. <https://doi.org/10.1016/j.humpath.2017.08.028> PMID: 28882699
26. Ohta A (2016) A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment. *Front Immunol* 7: 1–11.
27. Zhou L, Xu L, Chen L, Fu Q, Liu Z, et al. (2017) Tumor-infiltrating neutrophils predict benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer. *Oncoimmunology* 6: e1293211. <https://doi.org/10.1080/2162402X.2017.1293211> PMID: 28507798
28. Lee JJ, Jacobsen EA, Ochkur SI, McGarry MP, Condjella RM, et al. (2012) Human versus mouse eosinophils: "that which we call an eosinophil, by any other name would stain as red". *J Allergy Clin Immunol* 130: 572–584. <https://doi.org/10.1016/j.jaci.2012.07.025> PMID: 22935586
29. Jablonska J, Leschner S, Westphal K, Lienenklaus S, Weiss S (2010) Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. *J Clin Invest* 120: 1151–1164. <https://doi.org/10.1172/JCI37223> PMID: 20237412
30. Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, et al. (2010) Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. *Nat Med* 16: 219–223. <https://doi.org/10.1038/nm.2084> PMID: 20081861
31. Queen MM, Ryan RE, Holzer RG, Keller-Peck CR, Jorcyk CL (2005) Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. *Cancer Res* 65: 8896–8904. <https://doi.org/10.1158/0008-5472.CAN-05-1734> PMID: 16204061
32. Scapini P, Cassatella MA (2014) Social networking of human neutrophils within the immune system. *Blood* 124: 710–719. <https://doi.org/10.1182/blood-2014-03-453217> PMID: 24923297
33. Scapini P, Morini M, Tecchio C, Minghelli S, Di Carlo E, et al. (2004) CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A. *J Immunol* 172: 5034–5040. PMID: 15067085
34. Eruslanov EB, Bhojnagarwala PS, Quatromoni JG, Stephen TL, Ranganathan A, et al. (2014) Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. *J Clin Invest* 124: 5466–5480. <https://doi.org/10.1172/JCI77053> PMID: 25384214
35. Granot Z, Henke E, Comen EA, King TA, Norton L, et al. (2011) Tumor entrained neutrophils inhibit seeding in the premetastatic lung. *Cancer Cell* 20: 300–314. <https://doi.org/10.1016/j.ccr.2011.08.012> PMID: 21907922
36. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, et al. (2016) Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet* 388: 2128–2141. [https://doi.org/10.1016/S0140-6736\(16\)31322-8](https://doi.org/10.1016/S0140-6736(16)31322-8) PMID: 27609406
37. Santoro M, Melillo RM (2015) Genetics: The genomic landscape of papillary thyroid carcinoma. *Nat Rev Endocrinol* 11: 133–134. <https://doi.org/10.1038/nrendo.2014.209> PMID: 25421371
38. Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI (2010) Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. *Am J Surg* 200: 197–203. <https://doi.org/10.1016/j.amjsurg.2009.08.041> PMID: 20122680
39. Liu CL, Lee JJ, Liu TP, Chang YC, Hsu YC, et al. (2013) Blood neutrophil-to-lymphocyte ratio correlates with tumor size in patients with differentiated thyroid cancer. *J Surg Oncol* 107: 493–497. <https://doi.org/10.1002/jso.23270> PMID: 22996403
40. Lang BH, Ng CP, Au KB, Wong KP, Wong KK, et al. (2014) Does preoperative neutrophil lymphocyte ratio predict risk of recurrence and occult central nodal metastasis in papillary thyroid carcinoma? *World J Surg* 38: 2605–2612. <https://doi.org/10.1007/s00268-014-2630-z> PMID: 24809487
41. Muzio M, Re F, Sironi M, Polentarutti N, Minty A, et al. (1994) Interleukin-13 induces the production of interleukin-1 receptor antagonist (IL-1ra) and the expression of the mRNA for the intracellular (keratinocyte) form of IL-1ra in human myelomonocytic cells. *Blood* 83: 1738–1743. PMID: 7908231
42. Calzetti F, Tamassia N, Arruda-Silva F, Gasperini S, Cassatella MA (2017) The importance of being "pure" neutrophils. *J Allergy Clin Immunol* 139: 352–355.e356. <https://doi.org/10.1016/j.jaci.2016.06.025> PMID: 27567327
43. Borriello F, Iannone R, Di Somma S, Loffredo S, Scamardella E, et al. (2016) GM-CSF and IL-3 Modulate Human Monocyte TNF-alpha Production and Renewal in In Vitro Models of Trained Immunity. *Front Immunol* 7: 680. <https://doi.org/10.3389/fimmu.2016.00680> PMID: 28138327
44. Borriello F, Iannone R, Di Somma S, Vastolo V, Petrosino G, et al. (2017) Lipopolysaccharide-Elicited TSLPR Expression Enriches a Functionally Discrete Subset of Human CD14+ CD1c+ Monocytes. *J Immunol* 198: 3426–3435. <https://doi.org/10.4049/jimmunol.1601497> PMID: 28341671

45. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, et al. (2005) The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. *J Clin Invest* 115: 1068–1081. <https://doi.org/10.1172/JCI22758> PMID: 15761501
46. Trellakis S, Bruderek K, Dumitru CA, Gholaman H, Gu X, et al. (2011) Polymorphonuclear granulocytes in human head and neck cancer: Enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease. *Int J Cancer* 129: 2183–2193. <https://doi.org/10.1002/ijc.25892> PMID: 21190185
47. Waugh DJ, Wilson C (2008) The interleukin-8 pathway in cancer. *Clin Cancer Res* 14: 6735–6741. <https://doi.org/10.1158/1078-0432.CCR-07-4843> PMID: 18980965
48. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, et al. (2003) Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. *Blood* 101: 4660–4666. <https://doi.org/10.1182/blood-2003-01-0006> PMID: 12676775
49. Guttman-Yassky E, Nograles KE, Krueger JG (2011) Contrasting pathogenesis of atopic dermatitis and psoriasis—part II: immune cell subsets and therapeutic concepts. *J Allergy Clin Immunol* 127: 1420–1432. <https://doi.org/10.1016/j.jaci.2011.01.054> PMID: 21419481
50. Shi Y, Liu CH, Roberts AI, Das J, Xu G, et al. (2006) Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. *Cell Res* 16: 126–133. <https://doi.org/10.1038/sj.cr.7310017> PMID: 16474424
51. Stocks SC, Ruchaud-Sparagano MH, Kerr MA, Grunert F, Haslett C, et al. (1996) CD66: role in the regulation of neutrophil effector function. *Eur J Immunol* 26: 2924–2932. <https://doi.org/10.1002/eji.1830261218> PMID: 8977287
52. Condliffe AM, Chilvers ER, Haslett C, Dransfield I (1996) Priming differentially regulates neutrophil adhesion molecule expression/function. *Immunology* 89: 105–111. PMID: 8911147
53. Kutsuna H, Suzuki K, Kamata N, Kato T, Hato F, et al. (2004) Actin reorganization and morphological changes in human neutrophils stimulated by TNF, GM-CSF, and G-CSF: the role of MAP kinases. *Am J Physiol Cell Physiol* 286: C55–64. <https://doi.org/10.1152/ajpcell.00131.2003> PMID: 12954601
54. Peters SB, Abdelatif O, LiVolsi VA (1996) Intraepithelial Neutrophils in Thyroid Fine-Needle Aspiration: A Portent of Aggressive Thyroid Cancer? *Endocr Pathol* 7: 47–54. PMID: 12114679
55. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. *Cell* 144: 646–674. <https://doi.org/10.1016/j.cell.2011.02.013> PMID: 21376230
56. Galdiero MR, Marone G, Mantovani A (2017) Cancer Inflammation and Cytokines. *Cold Spring Harb Perspect Biol*.
57. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? *Lancet* 357: 539–545. [https://doi.org/10.1016/S0140-6736\(00\)04046-0](https://doi.org/10.1016/S0140-6736(00)04046-0) PMID: 11229684
58. Allavena P, Sica A, Solinas G, Porta C, Mantovani A (2008) The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. *Crit Rev Oncol Hematol* 66: 1–9. <https://doi.org/10.1016/j.critrevonc.2007.07.004> PMID: 17913510
59. Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, et al. (2013) Tumor associated macrophages and neutrophils in cancer. *Immunobiology* 218: 1402–1410. <https://doi.org/10.1016/j.imbio.2013.06.003> PMID: 23891329
60. Marone G, Varricchi G, Loffredo S, Granata F (2016) Mast cells and basophils in inflammatory and tumor angiogenesis and lymphangiogenesis. *Eur J Pharmacol* 778: 146–151. <https://doi.org/10.1016/j.ejphar.2015.03.088> PMID: 25941082
61. Galdiero MR, Varricchi G, Seaf M, Marone G, Levi-Schaffer F (2017) Bidirectional Mast Cell-Eosinophil Interactions in Inflammatory Disorders and Cancer. *Front Med (Lausanne)* 4: 103.
62. Varricchi G, Galdiero MR, Marone G, Granata F, Borriello F (2017) Controversial role of mast cells in skin cancers. *Exp Dermatol* 26: 11–17. <https://doi.org/10.1111/exd.13107> PMID: 27305467
63. Cunha LL, Marcello MA, Ward LS (2014) The role of the inflammatory microenvironment in thyroid carcinogenesis. *Endocr Relat Cancer* 21: R85–R103. <https://doi.org/10.1530/ERC-13-0431> PMID: 24302667
64. Cunha LL, Morari EC, Guihen AC, Razolli D, Gerhard R, et al. (2012) Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma. *Clin Endocrinol (Oxf)* 77: 918–925.
65. Woytschak J, Keller N, Krieg C, Impellizzieri D, Thompson RW, et al. (2016) Type 2 Interleukin-4 Receptor Signaling in Neutrophils Antagonizes Their Expansion and Migration during Infection and Inflammation. *Immunity* 45: 172–184. <https://doi.org/10.1016/j.immuni.2016.06.025> PMID: 27438770
66. de Oliveira S, Rosowski EE, Huttenlocher A (2016) Neutrophil migration in infection and wound repair: going forward in reverse. *Nat Rev Immunol* 16: 378–391. <https://doi.org/10.1038/nri.2016.49> PMID: 27231052

67. Hirt C, Eppenberger-Castori S, Sconocchia G, Iezzi G, Tornillo L, et al. (2013) Colorectal carcinoma infiltration by myeloperoxidase-expressing neutrophil granulocytes is associated with favorable prognosis. *Oncoimmunology* 2: e25990. <https://doi.org/10.4161/onci.25990> PMID: 24244897
68. Ribas A, Hu-Lieskovan S (2016) What does PD-L1 positive or negative mean? *J Exp Med* 213: 2835–2840. <https://doi.org/10.1084/jem.20161462> PMID: 27903604
69. Mishalian I, Granot Z, Fridlender ZG (2017) The diversity of circulating neutrophils in cancer. *Immunobiology* 222: 82–88. <https://doi.org/10.1016/j.imbio.2016.02.001> PMID: 26874580
70. Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, et al. (2016) Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. *Lancet* 388: 2115–2127. [https://doi.org/10.1016/S0140-6736\(16\)31324-1](https://doi.org/10.1016/S0140-6736(16)31324-1) PMID: 27609408
71. Jiang K, Lei J, Chen W, Gong Y, Luo H, et al. (2016) Association of the preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios with lymph node metastasis and recurrence in patients with medullary thyroid carcinoma. *Medicine (Baltimore)* 95: e5079.
72. Gong W, Yang S, Yang X, Guo F (2016) Blood preoperative neutrophil-to-lymphocyte ratio is correlated with TNM stage in patients with papillary thyroid cancer. *Clinics (Sao Paulo)* 71: 311–314.
73. Granot Z, Jablonska J (2015) Distinct Functions of Neutrophil in Cancer and Its Regulation. *Mediators Inflamm* 2015: 701067. <https://doi.org/10.1155/2015/701067> PMID: 26648665
74. Sims JE, Smith DE (2010) The IL-1 family: regulators of immunity. *Nat Rev Immunol* 10: 89–102. <https://doi.org/10.1038/nri2691> PMID: 20081871
75. Manukyan G, Papajik T, Gajdos P, Mikulkova Z, Urbanova R, et al. (2017) Neutrophils in chronic lymphocytic leukemia are permanently activated and have functional defects. *Oncotarget* 8: 84889–84901. <https://doi.org/10.18632/oncotarget.20031> PMID: 29156691
76. Barrera L, Montes-Servin E, Hernandez-Martinez JM, Garcia-Vicente MLA, Montes-Servin E, et al. (2017) CD47 overexpression is associated with decreased neutrophil apoptosis/phagocytosis and poor prognosis in non-small-cell lung cancer patients. *Br J Cancer* 117: 385–397. <https://doi.org/10.1038/bjc.2017.173> PMID: 28632731
77. Dinarello CA, Novick D, Puren AJ, Fantuzzi G, Shapiro L, et al. (1998) Overview of interleukin-18: more than an interferon-gamma inducing factor. *J Leukoc Biol* 63: 658–664. PMID: 9620656
78. Bouffi C, Rochman M, Zust CB, Stucke EM, Kartashov A, et al. (2013) IL-33 markedly activates murine eosinophils by an NF-kappaB-dependent mechanism differentially dependent upon an IL-4-driven auto-inflammatory loop. *J Immunol* 191: 4317–4325. <https://doi.org/10.4049/jimmunol.1301465> PMID: 24043894
79. Kanda Y, Osaki M, Okada F (2017) Chemopreventive Strategies for Inflammation-Related Carcinogenesis: Current Status and Future Direction. *Int J Mol Sci* 18.
80. Coussens LM, Tinkle CL, Hanahan D, Werb Z (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. *Cell* 103: 481–490. PMID: 11081634
81. Nozawa H, Chiu C, Hanahan D (2006) Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. *Proc Natl Acad Sci U S A* 103: 12493–12498. <https://doi.org/10.1073/pnas.0601807103> PMID: 16891410
82. Moloney JN, Cotter TG (2017) ROS signalling in the biology of cancer. *Semin Cell Dev Biol*.
83. Dumitru CA, Fechner MK, Hoffmann TK, Lang S, Brandau S (2012) A novel p38-MAPK signaling axis modulates neutrophil biology in head and neck cancer. *J Leukoc Biol* 91: 591–598. <https://doi.org/10.1189/jlb.0411193> PMID: 22262799
84. Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, et al. (2011) Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. *J Hepatol* 54: 948–955. <https://doi.org/10.1016/j.jhep.2010.08.041> PMID: 21145847
85. Ardi VC, Kupriyanova TA, Deryugina EI, Quigley JP (2007) Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. *Proc Natl Acad Sci U S A* 104: 20262–20267. <https://doi.org/10.1073/pnas.0706438104> PMID: 18077379